Related Experiment Video
Updated: Sep 25, 2026

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Neuropeptides in the therapy of Alzheimer's disease
1Prous Science, Barcelona, Spain.
Abstract:
Owing to the heterogeneity of cognitive dysfunctions in patients with Alzheimer's disease (AD), a single drug may not suffice. Combination therapy may be the most appropriate solution, but the cognitive networks in the brain have yet to be unraveled. In the years ahead, more comprehensive and precise knowledge of neurological function will allow scientists to pinpoint ever more sophisticated and effective therapeutic options for AD patients. In this review, the author discusses the currently known advantages and disadvantages of neuropeptides and how they may provide yet another drug target for AD treatment.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Dementia l: Introduction
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
